These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16506893)

  • 21. Diagnosing erectile dysfunction: instruments for the study of smooth muscle relaxation.
    Pescatori ES; Morgia G; Pirozzi-Farina F
    Int J Androl; 2005 Dec; 28 Suppl 2():56-60. PubMed ID: 16236066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological therapy in erectile dysfunction--current standards and new viewpoint].
    Schultheiss D; Stief CG; Truss MC; Jonas U
    Wien Med Wochenschr; 1997; 147(4-5):102-4. PubMed ID: 9190765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct androgen regulation of PDE5 gene or the lack thereof.
    Lin CS; Xin Z; Namiki M; Albersen M; Muller D; Lue TF
    Int J Impot Res; 2013 May; 25(3):81-5. PubMed ID: 23486196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiological roles and properties of potassium channels in corporal smooth muscle.
    Lee SW
    Drugs Today (Barc); 2000; 36(2-3):147-54. PubMed ID: 12879112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility.
    Ghalayini IF
    Int J Impot Res; 2004 Dec; 16(6):459-69. PubMed ID: 15229623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat.
    Ferrini MG; Kovanecz I; Sanchez S; Vernet D; Davila HH; Rajfer J; Gonzalez-Cadavid NF
    Biol Reprod; 2007 May; 76(5):915-23. PubMed ID: 17287493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-Thio-quinolinone maxi-K openers for the treatment of erectile dysfunction.
    Boy KM; Guernon JM; Sit SY; Xie K; Hewawasam P; Boissard CG; Dworetzky SI; Natale J; Gribkoff VK; Lodge N; Starrett JE
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5089-93. PubMed ID: 15380205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the relaxation responses of isolated cavernosal smooth muscles by endothelium-independent and endothelium-dependent vasodilators in diabetic men with impotence.
    Kim SC; Ahn SY; Park SH; Lee MY; Uhm DY
    J Korean Med Sci; 1995 Feb; 10(1):1-6. PubMed ID: 7598818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
    Francis SH; Morris GZ; Corbin JD
    Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The promise of inhibition of smooth muscle tone as a treatment for erectile dysfunction: where are we now?
    Jiang X; Chitaley K
    Int J Impot Res; 2012; 24(2):49-60. PubMed ID: 21975566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
    Rosen RC; McKenna KE
    Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
    Pickard R
    Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial comment on: chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.
    Usta MF
    Eur Urol; 2008 Jun; 53(6):1288-9. PubMed ID: 18243512
    [No Abstract]   [Full Text] [Related]  

  • 37. K+ channels and gap junctions in the modulation of corporal smooth muscle tone.
    Christ GJ
    Drug News Perspect; 2000 Feb; 13(1):28-36. PubMed ID: 12937650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro.
    Spektor M; Rodriguez R; Rosenbaum RS; Wang HZ; Melman A; Christ GJ
    J Urol; 2002 Jun; 167(6):2628-35. PubMed ID: 11992099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapy of erectile dysfunction].
    Kopa Z; Romics I
    Orv Hetil; 2010 Feb; 151(9):354-7. PubMed ID: 20159751
    [No Abstract]   [Full Text] [Related]  

  • 40. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Firoozi F; Longhurst PA; White MD
    BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.